A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ā„12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Sinocelltech Ltd.
- Registration Number
- NCT05239975
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ā„12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05239806
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ā„18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05238441
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ā„18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT05238454
A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Sinocelltech Ltd.
- Registration Number
- NCT05156645
The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 478
- Registration Number
- NCT05148091
- Locations
- šØš³
PetroChina Central Hospital, Langfang, Hebei, China
šØš³Anhui Provincial Hospital, Hefei, Anhui, China
šØš³Peking University First Hospital, Beijing, Beijing, China
A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 1800
- Registration Number
- NCT05060484
- Locations
- šØš³
Guanyun Country CDC, Nanjing, Jiangsu, China
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ā„18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05043285
- Locations
- š¦šŖ
Al Kuwait Hospital (Al Baraha Hospital), Dubai, United Arab Emirates
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ā„18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05043311
- Locations
- š¦šŖ
Al Kuwait Hospital (Al Baraha Hospital), Dubai, United Arab Emirates
A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT04921111
- Locations
- šØš³
Guanyun Country CDC, Nanjing, Jiangsu, China
Ā© Copyright 2024. All Rights Reserved by MedPath